A study performed by Cone Communications found that 87% of Americans would purchase products from businesses who advocate for social and environmental responsibility. Even more significantly, 76% would boycott businesses who behave in ways contrary to this.¹ For pharmaceutical organizations, sustainability is smart business – and not just because of the social acclamation. Increased efficiencies and cost reductions deliver a competitive advantage and increase the dollars available to bolster additional research. In this paper you will learn why sustainable practices, and investments should reach the real-estate portfolio your enterprise depends on.
Pharmaceutical Sustainability at Scale
